

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.  
2732.1016-029APPLICATION NO. 10/719,432  
Case App. No. 041,379INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

November 21, 2003

(Use several sheets if necessary)

APPLICANT  
Spiros Jamas et al.

FILING DATE

CONFIRMATION NO.

GROUP

1614

## U.S. PATENT DOCUMENTS

EXAM- INER INITIAL	REF. NO.	DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME
	AA	4,810,646	03/07/89	Jamas et al.
	AB	4,761,402	08/02/88	Williams et al.
	AC	4,739,046	04/19/88	DiLuzio et al.
	AD	4,138,479	02/06/79	Truscheit et al.
	AE	4,237,266	12/02/80	Sugiura et al.
	AF	4,707,471	11/17/87	Larm et al.
	AG	5,032,401	07/16/91	Jamas et al.
	AH	5,057,503	10/15/91	Czop et al.
	AI	5,322,841	11/02/92	Jamas et al.
	AJ	5,320,849	06/14/94	Hagiwara et al.
	AK	5,488,040	01/30/96	Jamas et al.
	AA2	5,532,223	07/02/96	Jamas et al.
	AB2	5,622,939	04/22/97	Jamas et al.
	AC2	3,943,247	03/09/76	Komatsu et al.
	AD2	5,504,079	04/02/96	Jamas et al.
	AE2	5,401,647	03/28/95	Tanaka et al.
	AF2	5,783,569	7/21/98	Jamas et al.
	AG2	5,817,643	10/06/98	Jamas et al.
	AH2	4,975,421	12/04/90	Williams et al.
	AI2	5,474,984	12/12/95	Tanaka et al.
	AJ2	4,946,450	08/07/90	Erwin
	AK2	4,992,540	02/12/91	Jamas et al.
	AA3	5,663,324	09/02/97	Jamas et al.
	AB3	5,633,369	05/27/97	Jamas et al.
	AC3	5,811,542	09/22/98	Jamas et al.

EXAMINER

DATE CONSIDERED

8-8-04

PTO-1449 REPRODUCED  INFORMATION DISCLOSURE CITATION IN AN APPLICATION  November 21, 2003 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2732.1016-029	APPLICATION NO. 10/719,432 Grant App. 5000/PA1,169
	APPLICANT Spiros Jamas et al.	
	FILING DATE	CONFIRMATION NO.
		GROUP

FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
✓	AL	59210901	06-APR-95	Japan (Abstract)	X
	AM	59045301	21-JUN-84	Japan (Abstract)	X
	AN	56076401	11-SEP-81	Japan (Abstract)	X
✓	AO	55071701	12-AUG-80	Japan (Abstract)	X
✓	AP	20764118	02-DEC-81	Great Britain	
✓	AQ	91/03495	21-MAR-91	PCT International	
	AL2	WO 94/04163	03-MAR-94	PCT International	
✓	AM2	WO 91/03248	31-MAR-91	PCT International	
✓	AN2	0463540	02-JAN-92	EPO	
✓	AQ2	94/03498	17-FEB-94	PCT International	
✓	AQ2	92/13896	20-AUG-92	PCT International	
✓	AQ2	94/03500	17-FEB-94	PCT International	
	AL3	0416343	13-MAR-91	EPC	
	AM3				
	AN3				
	AO3				
	AP3				
	AQ3				
	AL4				
	AM4				
	AN4				
	AO4				
	AP4				
	AQ4				
	AL5				
	AM5				

EXAMINER <i>CM</i>	DATE CONSIDERED 4-3-05
-----------------------	---------------------------

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.  
2732.1016-029APPLICATION NO. 10/719,432  
Conf. App. of 09/07/1,170INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

November 21, 2003

(Use several sheets if necessary)

APPLICANT  
Spiros Jamas et al.

FILING DATE

CONFIRMATION NO.

GROUP

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AR	Janusz, M.J., et al., "Isolation of Soluble Yeast $\beta$ -Glucans that Inhibit Human Monocyte Phagocytosis Mediated by $\beta$ -Glucans Receptors," <i>J. Immunol.</i> , 137:3270-3276 (1986).
AS	Manners, D.J., et al., "The Structure of a $\beta$ -(3)-D-Glucan from Yeast Cell Walls," <i>Biochem. J.</i> , 135:19-30 (1973).
AT	Fleet, G.H., et al., "Isolation and Composition of an Alkali-Soluble Glucan from the Cell Walls of <i>Saccharomyces cerevisiae</i> ," <i>J. Gen. Microbiol.</i> , 94:180-192 (1976).
AV	Miyazaki, T., et al., "Structural Examination of Antitumour, Water-Soluble Glucans from <i>Grifola umbellata</i> by Use of Four Types of Glucanase," <i>Carbohydrate Research</i> , 65:235-243 (1978).
AW	Reiskind, J.B. and Mullins, J.T., "Molecular Architecture of the Hyphal Wall of <i>Achlya ambisexualis</i> Paper II. Ultrastructural Analyses and a Proposed Model," <i>Can. J. Microbiol.</i> , 27:1100-1105 (1981).
AX	Latge, J.P., et al., "Composition Chimique et Ultrastructure des Parois des Hyphaux et des Azygospores de <i>Conidiobolus obscurus</i> ," <i>Can. J. Microbiol.</i> , 30:1507-1421 (1984).
AY	Sherwood, E.R., et al., "Soluble Glucan and Lymphokine-Activated Killer (LAK) Cells in the Therapy of Experimental Hepatic Metastases," <i>Chemical Abstracts</i> , 108:179752v (1988).
AT	Hara, C., et al., "A Branched (1-3)- $\beta$ -D-Glucan from a Water Extract of <i>Dictyophora indusiata</i> FISCH," <i>Carb. Res.</i> , 145:237-246 (1986).
AZ	Goldman, R., "Induction of a $\beta$ -1,3-D-Glucan Receptor in P388D1 Cells Treated with Retinoic Acid or 1,25-dihydroxyvitamin D <sub>3</sub> ," <i>Immunology</i> , 63:319-324 (1988).
AR2	Konopski, A., et al., "Phagocytosis of $\beta$ -1,3-D-Glucan-Derivatized Microbeads by Mouse Peritoneal Macrophages Involves Three Different Receptors," <i>Scand. J. Immunol.</i> , 33:297-306 (1991).
AS2	Williams, D.L., et al., "Development of a Water-Soluble, Sulfated (1-3)- $\beta$ -D-Glucan Biological Response Modifier Derived from <i>Saccharomyces cerevisiae</i> ," <i>Carbohydrate Research</i> , 235:247-257 (1992).
AT2	Williams, D.L., et al., "A Sequential Multi-Assay Protocol for the Preclinical Assessment of Natural Product Complex Carbohydrate Immunomodulators," <i>Develop. Biol. Standard.</i> , 77:129-136(1992).

EXAMINER

*CM*

DATE CONSIDERED

4-3-05

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.  
2732.1016-029APPLICATION NO. 10/719,432  
Conf. App. No. 241-170INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

November 21, 2003

(Use several sheets if necessary)

APPLICANT  
Spiros Jamas et al.

FILING DATE

CONFIRMATION NO.

GROUP

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AU2	Williams, D.L., et al., Development, Physiochemical Characterization and Preclinical Efficacy Evaluation of a Water Soluble Glucan Sulfate Derived from <i>Saccharomyces cerevisiae</i> , "Immunopharmacology," 22:139-156 (1991).
AV2	Bacon, J., et al., "The Glucan Components of the Cell Wall of Baker's Yeast ( <i>Saccharomyces cerevisiae</i> ) Considered in Relation to its Ultrastructure," <i>Biochem. J.</i> , 114:557-567 (1969).
AW2	Vestnick Federalniho Uradu Pro Vynalezy, 10:111 (1989).
AX2	Vestnick Federalniho Uradu Pro Vynalezy, 11:122-123 (1989).
AY2	Onderdonk, A.B., et al., "Anti-Infective Effect of Poly- $\beta$ 1-6-Glucotrisyl- $\beta$ 1-3-Glucopyranose Glucan In Vivo," <i>Infect. Immun.</i> , 60:1642-1647 (1992).
AZ2	Abel, G. and Czop, J.K., "Activation of Human Monocyte GM-CSF and TNF- $\alpha$ Production by Particulate Yeast Glucan," International Congress for Infectious Diseases, Montreal Canada (Abstract) July 15-19, 1990.
AR3	Chihara, G., et al., "Lentinan as a Host Defense Potentiator (HPD)," <i>Int. J. Immunotherapy</i> , 4:145-154 (1989).
AS3	Sherwood, E.R., et al., "Enhancement of Interleukin-1 and Interleukin-2 Production by Soluble Glucan," <i>Int. J. Immunopharm.</i> , 9(3):261-267 (1987).
AT3	Williams, D.L., et al., "Pre-clinical Safety Evaluation of Soluble Glucan," <i>Int. J. Immunopharm.</i> , 10(4):405-414 (1988).
AU3	Browder, W., et al., "Beneficial Effect of Enhanced Macrophage Function in the Trauma Patient," <i>Ann. Surg.</i> , p. 605-613 (1990).
AV3	Jamas, et al., "A Novel Class of Macrophage-Activating Immunomodulators," <i>ACS Symposium Series, Polymeric Drugs and Delivery Systems</i> , Chapter 5, pp. 44-51 (1991).
AW3	Shiota, M., et al., "Comparison of $\beta$ -Glucan Structures in a Cell Wall Mutant of <i>Saccharomyces cerevisiae</i> and the Wild Type," <i>J. Biochem.</i> , 98:1301-1307 (1985).
AX3	Jamas, et al., "PGG-A Novel Class of Macrophage Activating Immunomodulators," International Congress for Infectious Diseases, Montreal, Canada (Abstract), July 15-19, 1990.

EXAMINER

DATE CONSIDERED

4-3-05

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.  
2732.1016-029APPLICATION NO. 10/719,432  
Cont. App. of 097641,110

## INFORMATION DISCLOSURE CITATION

IN AN APPLICATION

November 21, 2003

(Use several sheets if necessary)

APPLICANT  
Spiros Jamas et al.

FILING DATE

CONFIRMATION NO.

GROUP

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AY3	Katzen, et al., "PGG, a Glucose Polymer, Primes Interleukin-1 and Tumor Necrosis Factor Production," International Congress for Infectious Diseases, Montreal, Canada (Abstract), July 15-19, 1990.
AZ3	Shah, et al., "Influence of PGG on the Phagocytosis of <i>Staphylococcus aureus</i> or <i>Escherichia coli</i> ," International Congress for Infectious Diseases, Montreal, Canada (Abstract), July 15-19, 1990.
AR4	Onderdonk, A.B., "Effect of a New Carbohydrate Polymer on Survival in a Mouse Model for Experimental <i>E. coli</i> Sepsis," International Congress for Infectious Diseases, Montreal, Canada (Abstract), July 15-19, 1990.
AS4	Arbo, A. and Santos, J.I., "Effect of PGG on Neutrophil (PMN) Function in Experimental Malnutrition," International Congress for Infectious Diseases, Montreal, Canada (Abstract), July 15-19, 1990.
AP4	Onderdonk, A.B., et al., "Protective Effect of a New Carbohydrate Polymer in a Rat Model for Experimental Intraabdominal Sepsis," First International Congress on Biological Response Modifiers, Quebec, Canada, (Abstract), March, 1991.
AT4	Lagrange, P.H. and Fourgeaud, M., "Enhanced Natural Resistance Against Severe Disseminated <i>Candida albicans</i> ," <i>Int'l J. Experimental Clin. Chemotherapy</i> , 40(1):48-55 (1991).
AV4	Sakurai, et al., "Intravenously Administered (1-3)- $\beta$ -D-Glucan, SSG, Obtained from <i>Sclerotinia sclerotiorum</i> IFO9395 Augments Murine Peritoneal Macrophage Function <i>In Vivo</i> ," <i>Chem. Pharm. Bull.</i> , 40(8):2120-2124 (1992).
AW4	Jamas, S., et al., "PGG-A Novel Class of Macrophage Activating Immunomodulators," <i>Polymer Preprints</i> , 31:194-195 (1990).
AX4	Sasaki, et al., "Antitumor Activity of Degraded Products of Lentinan: Its Correlation with Molecular Weight," <i>Gann</i> , 67:191-195 (1976).
AY4	Di Luzio, et al., "Comparative Tumor-Inhibitory and Anti-Bacterial Activity of Soluble and Particulate Glucan," <i>Int. J. Cancer</i> , 24:773-779 (1979).
AZ4	Burgaleta, C. and Golde, D.W., "Effect of Glucan of Granulopoiesis and Macrophage Genesis in Mice," <i>Cancer Research</i> , 37:1739-1742 (1977).
ARS	Kenyon, A.J., "Delayed Wound Healing in Mice Associated with Viral Alteration of Macrophages," <i>Am. J. Vet. Res.</i> , 44(4):652-656 (1983).

EXAMINER

DATE CONSIDERED

4-3-05

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 2732.1016-029	APPLICATION NO. 10/779,432 Outer App. 50018411-170
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		APPLICANT Spiros Jarnas et al.
November 21, 2003 (Use several sheets if necessary)	FILING DATE	CONFIRMATION NO.
		GROUP

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
ASS	Babineau, T., et al., "Randomized Phase I/II Trial of a Macrophage-Specific Immunomodulator PGG-Glucan (Betafектин™) in High Risk Surgery Patients," Clinical Congress of the American College of Surgeons, San Francisco, CA, October 11, 1993.	
ATS	Babineau, T., et al., "Randomized Multicenter Phase I/II Trial of a Macrophage-Specific Immunomodulator (PGG-Glucan) in High Risk Surgery Patients," Surgical Infection Society Meeting, April, 29, 1994.	
AUS	Adachi, Y., et al., "Enhancement of Cytokine Production by Macrophages Stimulated with (1-3)- $\beta$ -D-Glucan, Grifolan (GRN), Isolated from <i>Grifola frondosa</i> ," <i>Biol. Pharm. Bull.</i> , 17(12):1554-1560 (1994).	
AVS	Babineau, T.J., et al., "A Phase II Multicenter, Double-blind, Randomized, Placebo-Controlled Study of Three Dosages of an Immunomodulator (PGG-Glucan) in High Risk Surgical Patients", <i>Archives of Surgery</i> , 129:1204-1210 (1994).	
AWS	Babineau, T.J., et al., "Randomized Phase I/II Trial of a Macrophase-Specific Immunomodulator (PGG-Glucan) in High Risk Surgical Patients", <i>Annals of Surgery</i> , 220(5):601-609 (1994).	
AKS	Norton, J.A., "Biological Therapy of Sepsis", <i>Annals of Surgery</i> , 220(5):599-600 (1994).	
AT9	"Tumor Necrosis Factor: A Biological Enigma," Science Impact, pp. 5-6, June 1989.	
AZS	Dinarello, C.A. and Neta, R., "An Overview on Interleukin-1 as a Therapeutic Agent", <i>Biotherapy</i> , 1:245-254 (1989).	
AR6	Van der Meer, J.W.M., et al., "Concentrations of Immunoreactive Human Tumor Necrosis Factor Alpha Produced by Human Mononuclear Cells In Vitro," <i>Journal of Leukocyte Biology</i> , 43:216-223 (1988).	
AS6	Dinarello, C.A., "Interleukin-1," <i>Reviews of Infectious Diseases</i> , 6(1):51-95 (1984).	
AT6	Duvic, M., et al., "Glucan-Induced Keratoderma in Acquired Immunodeficiency Syndrome," <i>Arch Dermatol.</i> , 123:751-756	
AU6	Adachi, Y., et al., "Macrophage Activation in Vitro by Chemically Cross-Linked-(1-3)- $\beta$ -D-Glucans," <i>Chem. Pharm. Bull.</i> , 38(4):988-992 (1990).	
AV6	Sietsma, J.H. and Wessels, J.G.H., "Solubility of (1-3)- $\beta$ -D-Glucan in Fungal Walls: Importance of Presumed Linkage between Glucan and Chitin", <i>J. Gen. Microbiology</i> , 125:209-212 (1981).	

EXAMINER	DATE CONSIDERED
<i>CM</i>	4-3-05